Diabetes Mellitus
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.
Interventions
Sponsors
Takeda
Study design
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Inclusion criteria
1. The participant is an outpatient. 2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Exclusion criteria
1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.（e.g., subjects who require hospitalization or subjects who were hospitalized within 24 weeks prior to the commencement of the observation period) 2. The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glycosylated hemoglobin (HbA1c) | 24 weeks. | Measurement of change in HbA1c (ratio of hemoglobin bound to glucose). |
Countries
Japan
Outcome results
None listed